Clinical trials: Leukemia, Prolymphocytic Leukemia, Small
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
This phase II trial studies how well sotrastaurin acetate works in treating patients with chronic lymphocytic leukemia, small lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation that has returned or that…
- Conditions
- Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT02285244
- Testing
- sotrastaurin acetate, pharmacological study, laboratory biomarker analysis
- Sponsor
- James Blachly
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
- Trial name
- PCYC-1109-CA (NCT01217749)
- Testing
- PCI-32765, ofatumumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Pharmacyclics LLC.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Chronic Lymphocytic Leukemia
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with alvocidib in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT00735930
- Testing
- Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT02556931
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01558778
- Testing
- management of therapy complications, musculoskeletal complications management/prevention
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005580
- Testing
- bryostatin 1, fludarabine phosphate
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Virginia Commonwealth University
B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
This phase II trial is studying how well flavopiridol works in treating patients with chronic lymphocytic leukemia or prolymphocytic leukemia.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00098371
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
This phase II trial studies how well ibrutinib or idelalisib works in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that is persistent or has returned (relapsed) after…
- Conditions
- Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02662296
- Testing
- Ibrutinib, Idelalisib
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned after a period of…
- Conditions
- Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia
- Trial name
- NCT01886859
- Testing
- Ibrutinib, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)